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Abstract
Objectives. To identify molecular differences between chondrocytes from osteophytic and articular cartilage tissue
from OA patients.
Methods. We investigated genes and pathways by combining genome-wide DNA methylation, RNA sequencing and
quantitative proteomics in isolated primary chondrocytes from the cartilaginous layer of osteophytes and matched areas
of low- and high-grade articular cartilage across nine patients with OA undergoing hip replacement surgery.
Results. Chondrocytes from osteophytic cartilage showed widespread differences to low-grade articular cartilage
chondrocytes. These differences were similar to, but more pronounced than, differences between chondrocytes from
osteophytic and high-grade articular cartilage, and more pronounced than differences between high- and low-grade
articular cartilage. We identified 56 genes with significant differences between osteophytic chondrocytes and low-grade
articular cartilage chondrocytes on all three omics levels. Several of these genes have known roles in OA, including
ALDH1A2 and cartilage oligomeric matrix protein, which have functional genetic variants associated with OA from
genome-wide association studies. An integrative gene ontology enrichment analysis showed that differences between
osteophytic and low-grade articular cartilage chondrocytes are associated with extracellular matrix organization, skeletal
system development, platelet aggregation and regulation of ERK1 and ERK2 cascade.
Conclusion. We present a first comprehensive view of the molecular landscape of chondrocytes from osteophytic
cartilage as compared with articular cartilage chondrocytes from the same joints in OA. We found robust changes at
genes relevant to chondrocyte function, providing insight into biological processes involved in osteophyte development
and thus OA progression.
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. Significant cross-omics differences between osteophytic and low-grade articular chondrocytes identified for 56 genes.
. Genes with cross-omics differences include ALDH1A2 and COMP; both contain genetic variants associated with
osteoarthritis.
Introduction
OA is a degenerative joint disease characterized clinically
by pain and loss of physical function [1]. It is very
common, affecting >40% of individuals over the age of
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70 years [2]. There is no curative therapy; end-stage
disease is treated by joint replacement surgery. This pro-
cedure provides an opportunity to directly examine and
characterize disease tissue from patients using genomic
technologies.
A key feature of OA is cartilage degeneration, and several
genomics studies have investigated the molecular charac-
teristics of this process (e.g. reviewed in [3]). However, an-
other important feature that can develop in joints affected
by OA is the osteophyte, an area of apparent new tissue
formation consisting of a cartilage-topped bony outgrowth.
Osteophytes can have a significant clinical impact on both
pain and loss of movement and are a typical radiographic
feature of OA [4]. Osteophytes arise primarily on the mar-
gins of the articular cartilage from cells of the periosteum or
synovium by a process of endochondral ossification within
newly forming fibrocartilage [5]. While the pathogenesis of
osteophytes has been studied in mice [5], there is still much
to be learned from the molecular characterization of these
important structures, particularly in human joints.
A previous study of osteophytic cartilage in the knee
investigated gene expression using a microarray and sug-
gested large differences compared with ‘macroscopically
intact’ articular cartilage [6]. The authors hypothesized that
cells in the osteophyte transition between chondrocyte
and hypertrophic chondrocyte phenotypes, as opposed
to a stable chondrocyte phenotype in articular cartilage.
In this proof-of-concept study, we report the first ana-
lysis of hip OA patient tissue using integrated multi-omics
across genome-wide DNA methylation, RNA sequencing
and quantitative proteomics to obtain a molecular portrait
of chondrocytes from the cartilaginous layer of osteo-
phytes. We identify key molecular players linked to this
aspect of the disease and its pathogenesis.
Methods
More details, including references, are given in the sup-
plementary Methods, available at Rheumatology online.
Patients and samples
The study complies with the Declaration of Helsinki. Tissue
samples were collected under National Research Ethics
approval reference 11/EE/0011, Cambridge Biomedical
Research Centre Human Research Tissue Bank,
Cambridge University Hospitals, UK. Three samples each
were collected from nine patients (six women, three men,
age 4484 years) undergoing hip joint replacement surgery
for OA. All patients provided written informed consent before
participation. Cartilage tissue was classified macroscopically
for each femoral head as: low-grade, with a smooth surface
and no obvious evidence of damage or fibrillation; high-
grade, with damaged and fibrillated cartilage; and osteo-
phytic, from the cartilaginous layer of osteophytes located
mainly around the margins of the articular surface (sample
extraction section of the supplementary methods and sup-
plementary Figs S1 and S2, available at Rheumatology
online). In each zone, a cartilage sample was removed,
with subsequent extraction of DNA, RNA and protein.
Cartilage from all structural layers was obtained, with care
taken to avoid the removal of non-cartilage tissue. Details for
histological examination, chondrocyte preparation, as well
as extraction of DNA, RNA and protein are described in
the supplementary methods, sample extraction section,
available at Rheumatology online.
Proteomics
Liquid chromatography -mass spectrometry (LC-MS) ana-
lysis was performed on the Dionex Ultimate 3000 UHPLC
system coupled with the Orbitrap Fusion Tribrid Mass
Spectrometer (Thermo Fisher Scientific, Waltham, MA,
USA). Abundance values were normalized by the sum of
all protein abundances in a given sample, then log2-trans-
formed and quantile normalized. No protein was detected
in only osteophytic or only articular chondrocytes. Hence
we restricted the analysis to 4653 proteins that were quan-
tified in all individuals and tissues. Details for sample pro-
cessing, LC-MS analysis, protein identification and
quantification are described in the supplementary meth-
ods, proteomics section, available at Rheumatology online.
RNA sequencing
Multiplexed libraries were sequenced on Illumina HiSeq 2000
(Illumina Inc., San Diego, CA, USA; 75 bp paired-end read
length) and a cram file was produced for each sample. We
obtained transcript-level quantification using salmon 0.7.2
[7]. After quality control, we retained 14 029 genes. Details
for sample processing and read quantification are described
in the supplementary methods, RNA sequencing section,
available at Rheumatology online.
Methylation
Methylation was assayed using the Illumina 450k
BeadChip (Illumina Inc., San Diego, CA, USA). The result-
ing idat files were parsed and QCed using ChAMP [8] in R,
yielding 424 705 probes. The probe beta values were
normalized using the funnorm method [9] in R, and con-
verted to M-values. Details for Illumina 450k BeadChip
processing and quality control are described in the sup-
plementary methods, methylation section, available at
Rheumatology online.
Differential analysis
The proteomics, gene expression, and probe methylation
differential analyses were carried out using limma [10] in
R. We used a within-individual paired sample design, that
is, the individual ID as a covariate in the comparison of
osteophytic to low-grade, osteophytic to high-grade and
high-grade to low-grade tissue. A Benjamini-Hochberg
false discovery rate (FDR) was applied to each analysis
to correct for multiple testing. Differentially methylated re-
gions (DMRs) were identified using the DMRcate R pack-
age [11].
Principal component analysis
Principal component analyses were carried out using the
prcomp function in R for each omics level, based on sig-
nificant differences between osteophytic and low-grade
cartilage at 0.1% FDR.
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Gene identifier mapping
To map Ensembl gene IDs to gene names and vice versa,
we used the assignment in Ensembl (downloaded from
Ensembl biomart, GRCh38.p7). We only included in-
stances where a unique Ensembl gene ID corresponded
to a unique gene name.
UK Biobank association analysis
We applied MAGMA v1.06 [12] to test the joint association
of genetic variants in the 56 genes changed between
osteophytic and low-grade articular cartilage on all three
molecular levels. We used genetic association data from
UK Biobank, including 2396 hospital-diagnosed hip OA
cases and 9593 non-OA controls based on ICD 10 and/
or 9 codes; controls were not diagnosed with any muscu-
loskeletal disorders, symptoms or signs. Further details of
the dataset, including quality control, are described in the
supplementary methods, UK Biobank association analysis
section, available at Rheumatology online.
Each gene was assigned the single nucleotide poly-
morphisms (SNPs) located between the gene’s start and
stop sites based on NCBI 37.3 gene definitions. For each
gene, we used the combined statistic based on the sum of
SNP log-P-values and the lowest SNP P-values, as recom-
mended by MAGMA. Linkage disequilibrium (LD) was calcu-
lated from a subset of the UK Biobank samples (see
supplementary methods, UK Biobank association analysis
section, available at Rheumatology online). We then tested
whether the 56 genes are more associated with OA than
expected by chance, correcting for the potentially confound-
ing effects of sample size, gene size, gene density and the
inverse of the mean minor allele count in the gene, as well as
the log of these variables, as recommended.
Integrative Gene Ontology gene set analysis
Gene Ontology (GO) [13] biological process and molecular
function gene annotations were obtained from Ensembl
Biomart. We followed the integrative cross-omics analysis
from [14], as described in detail in the supplementary
methods, Gene Ontology gene-set analysis section, avail-
able at Rheumatology online. Briefly, enrichment of each
annotation for each of the three omics levels was as-
sessed using a one-sided hypergeometric test, the P-
values integrated across the three omics levels followed
by randomizations. Significance was defined at 5% FDR.
We excluded annotations that were enriched in only one
of the omics levels, or where fewer than five genes con-
tributed to the enrichment on at least two omics levels.
Results
Widespread differences between osteophytic and
articular cartilage
First, we examined genome-wide methylation, gene ex-
pression and protein abundance differences between
osteophytic and low-grade articular cartilage. At each mo-
lecular level, we found widespread differences at 0.1%
FDR. In particular, we found significant differences in pro-
tein abundance for 942 of 4653 proteins (supplementary
Table S1, available at Rheumatology online), in gene ex-
pression for 3601 of 14 029 genes (supplementary Table
S2, available at Rheumatology online), and 3161 DMRs
that overlapped 3277 genes (supplementary Table S3,
available at Rheumatology online).
Second, we also examined molecular differences be-
tween chondrocytes from osteophytic and high-grade ar-
ticular cartilage. Fewer differences were significant at 0.1%
FDR: protein abundance differences for 517 of 2653 genes
(supplementary Table S1, available at Rheumatology online),
gene expression differences for 1512 of 14 029 genes
(supplementary Table S2, available at Rheumatology online)
and 1113 DMRs overlapping 1113 genes (supplementary
Table S4, available at Rheumatology online). However, glo-
bally, the gene expression differences between osteophytic
and high-grade cartilage were similar to the differences be-
tween osteophytic and low-grade articular cartilage (Fig. 1a
and b; for estimates of the log-fold-differences in gene ex-
pression and protein abundance, the 95% CIs overlap for
97.9% of genes for gene expression and 97.6% of genes for
protein abundance). Moreover, for both gene expression
and protein abundance levels, of the genes significant at
0.1% FDR in a given comparison (osteophytic/low-grade
or osteophytic/high-grade), 599.5% show the same direc-
tion of change in the other comparison and 590% are at
least nominally significant. Similarly, of the genes contained
in DMRs at 0.1% FDR in one comparison, 593.5% are
contained in DMRs at 5% FDR in the other comparison.
This suggests that the differences between osteophytic
and low-grade articular cartilage are similar to, but more
pronounced than the differences between osteophytic
and high-grade articular cartilage. In agreement with
this, on each omics level, we found that a principal com-
ponent analysis based on the significant differences
between osteophytic and low-grade articular cartilage
separated the osteophytic cartilage from both the low-
grade and the high-grade articular cartilage samples
(Fig. 2). Hence we took the comparison of chondrocytes
from osteophytic and low-grade articular cartilage as the
basis for further analyses.
Differences between osteophytic and low-grade
articular cartilage are correlated with differences
between high- and low-grade articular cartilage
At any given level of significance, we identified far more
significant differences in the comparison of osteophytic
and low-grade articular cartilage than in the comparison
of high- and low-grade articular cartilage. For example, at
0.1% FDR, we found no protein with differential abun-
dance between high- and low-grade articular cartilage
(supplementary Table S1, available at Rheumatology
online), only one gene with differential RNA expression
(supplementary Table S2, available at Rheumatology
online), and no differentially methylated regions.
The differences observed between osteophytic and
low-grade cartilage are significantly correlated with the
differences found between high- and low-grade articular
cartilage (Fig. 1c and d; gene expression: Spearman
r= 0.62, protein abundance: r= 0.47; both P< 1015).
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FIG. 1 Gene expression and protein abundance differences between osteophytic chondrocytes, low-grade, and high-
grade articular chondrocytes
(A and B) Differences between osteophytic and low-grade articular chondrocytes are correlated with differences be-
tween osteophytic and high-grade articular chondrocytes for protein abundance (A) and gene expression (B). (C and D)
Differences between osteophytic and low-grade articular chondrocytes are correlated with differences between
high- and low-grade articular chondrocytes for protein abundance (C) and gene expression (D). (E) Differences in gene
expression and protein abundance identified between osteophytic and low-grade articular chondrocytes are correlated.
Each point represents one gene. Black: genes with significant changes between osteophytic and low-grade articular
cartilage at 0.1% FDR. Red: genes with significant changes on both protein and RNA level between osteophytic and
low-grade articular chondrocytes at 0.1% FDR.
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The direction of difference (increase or decrease) in osteo-
phytic compared with low-grade articular chondrocytes
agrees with the direction of difference in high-grade com-
pared with low-grade articular chondrocytes for 74% of
genes on mRNA level and for 66% of genes on protein
level.
In agreement with this, the vast majority of genes with
significant mRNA or protein level differences between
osteophytic and low-grade articular cartilage also show
the same direction of difference in high-grade compared
with low-grade articular cartilage (gene expression:
90.1%, protein abundance: 86.5%; both P< 1015; sup-
plementary Tables S1 and S2, available at Rheumatology
online). However, the magnitude of the log-fold-differ-
ences between the high- and low-grade articular chondro-
cytes is smaller (gene expression: 99.5% of 3601
significant genes and 75.4% of all genes, protein abun-
dance: 99.9% of 942 significant proteins and 73.9% of all
proteins).
Gene-level integration across multiple omics levels
RNA sequencing and proteomics
There was a significant positive correlation of the differ-
ences in gene expression and protein abundance identi-
fied between osteophytic and low-grade articular cartilage
in the proteomics and the RNA sequencing data (Fig. 1e;
Spearman r= 0.31, P< 1015; based on 4345 genes pre-
sent in both). We identified 309 genes with significant dif-
ferences on both RNA and protein level at 0.1% FDR,
88.7% of these differences were directionally concordant
(binomial P< 1015).
Methylation, RNA sequencing and proteomics
We found 56 genes that showed differences in protein
abundance and gene expression levels, and also over-
lapped a DMR between osteophytic and low-grade articu-
lar cartilage (Table 1). The direction of change on RNA and
protein level agreed for 52 of the 56 genes (binomial
P< 1010). For all 56 genes, the direction of difference be-
tween osteophytic and high-grade articular chondrocytes
is the same as the direction of difference between osteo-
phytic and low-grade articular chondrocytes, and 42 genes
also have evidence for difference between osteophytic and
high-grade articular chondrocytes across all three molecu-
lar levels at 5% FDR or lower (Table 1).
Link to genetic variants associated with OA
Of the 56 genes that showed significant differences be-
tween osteophytic and low-grade articular cartilage on all
three molecular levels, two have been robustly associated
with OA in published genome-wide association studies.
Both also show directionally concordant, significant RNA
and protein level differences between osteophytic and
high-grade articular chondrocytes at 0.1% FDR, and are
contained in DMRs at 5% FDR.
COMP demonstrates significantly lower gene and pro-
tein levels in osteophytic compared with low-grade articu-
lar cartilage, and is located in a hyper-methylated region.
The c.1141 G>C (p.Asp369His) missense variant in the
gene has been found to significantly increase the risk of
OA in a study of hip OA patients who underwent joint
replacement surgery [15].
ALDH1A2 also displays significantly reduced gene and
protein levels in osteophytic compared with low-grade ar-
ticular cartilage, and is located in a hyper-methylated
region. Several genetic variants in and close to ALDH1A2
have been associated with severe hand OA [16]. The most
strongly associated variant is rs12907038; the risk allele
has been associated with a decrease of ALDH1A2 gene
expression, and another associated variant has also
been associated with allelic imbalance in ALDH1A2 gene
expression [16].
We further tested the joint association of all 56 genes
with susceptibility to OA using an unpublished dataset
from UK Biobank (2396 hip OA cases, 9593 non-OA
FIG. 2 PCA separates osteophytic from low- and high-grade articular cartilage
PCA based on proteomics data (A), RNA sequencing data (B) and probe methylation data (C). Each point represents one
sample. The PCA was carried out on the proteins or genes with significant differences or within DMRs between osteo-
phytic and low-grade articular cartilage; the plots show that these expression or methylation patterns also separate
osteophytic from degraded cartilage. PCA: principal component analysis.
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TABLE 1 Genes with cross-omics significant differences between osteophytic and low-grade articular chondrocytes
Gene
Gene DMPs
in DMRs
Prop
BetaFC>0
DMPs
RNA
logFC
RNA
FDR
Protein
logFC
Protein
FDR ENSG
O vs H
5% FDR
ACTB 4 0 0.9 9.48E-06 0.34 3.93E-04 075624
ALDH1A2* 4 1 2.89 1.08E-07 3.29 1.44E-09 128918 Y
ALDH1A3 10 1 1.89 3.02E-08 2.79 2.93E-08 184254 Y
ARHGDIA 4 1 0.48 2.35E-05 0.37 6.60E-05 141522 Y
BLVRA 3 1 0.63 3.85E-06 0.33 4.50E-04 106605 Y
CASP4 2 0 0.87 1.53E-06 0.61 9.85E-04 196954
CHDH 3 1 1.68 3.09E-06 1.32 8.92E-05 016391 Y
CHI3L2 4 0.25 0.84 7.07E-05 0.97 7.33E-04 064886 Y
CHST6 2 1 0.72 8.75E-05 0.73 9.80E-05 183196 Y
CILP 7 1 4.44 2.55E-08 3.55 1.07E-06 138615 Y
COMP* 13 1 1.16 3.10E-05 2.72 2.88E-06 105664 Y
CPPED1 1 1 0.9 1.15E-05 0.69 1.18E-05 103381 Y
CPT1A 8 0.625 0.8 9.15E-04 0.91 4.64E-05 110090
CSRP1 5 0 0.39 5.37E-04 0.36 3.66E-04 159176 Y
CYR61 5 1 2.09 2.83E-06 1.82 4.75E-07 142871 Y
DCN 3 1 1.06 1.15E-04 1.85 8.29E-05 011465
EFHD1 3 1 2.56 1.79E-06 0.79 3.98E-04 115468
EMILIN1 2 1 0.91 3.67E-05 1.73 5.11E-08 138080 Y
EMILIN3 3 1 2.65 1.15E-06 2.96 4.11E-06 183798 Y
FAM162A 1 0 0.39 1.77E-04 0.74 1.24E-05 114023
FGF1 14 1 3.61 9.36E-08 2.15 1.01E-08 113578 Y
FIBIN 3 1 1.22 1.04E-05 2.73 1.53E-05 176971 Y
GALE 3 1 1.31 7.84E-06 1.42 2.54E-08 117308 Y
GNAS 2 1 0.37 4.49E-04 0.45 5.76E-05 087460 Y
IDUA 1 1 0.57 9.82E-05 0.34 9.73E-04 127415
IFI16 5 0 1.67 7.71E-05 1.21 3.55E-06 163565 Y
IL6 4 0.5 4.27 2.62E-04 1.61 2.40E-04 136244 Y
KRT8 9 1 2.29 8.55E-09 2.73 2.54E-08 170421 Y
MMP13 4 0 3.16 1.95E-05 2.51 6.43E-08 137745 Y
NEBL 3 1 2.22 1.49E-07 1.49 8.84E-07 078114 Y
NME2 6 1 0.53 4.07E-04 0.41 1.05E-04 243678
OSBPL10 4 1 1.51 1.08E-07 -0.51 2.84E-04 144645
OSBPL3 2 0 1.36 1.19E-05 1.28 6.86E-06 070882 Y
PAPSS2 2 1 0.95 1.82E-06 0.62 6.16E-05 198682
PDLIM4 3 1 1.3 4.22E-05 0.63 1.19E-05 131435
PGM1 1 1 0.57 2.82E-07 0.84 4.10E-06 079739 Y
PRKCZ 29 1 1.46 1.56E-06 0.83 4.52E-05 067606 Y
PSTPIP1 3 1 1.51 2.99E-04 0.56 2.39E-04 140368 Y
PTPRE 2 0.5 0.77 5.24E-04 0.74 7.21E-05 132334 Y
S100A1 2 1 1.97 1.75E-05 1.26 3.61E-05 160678 Y
SCRN1 2 1 0.74 7.21E-05 0.95 3.52E-05 136193 Y
SERPINA5 3 1 1.76 4.16E-08 1.58 1.19E-05 188488 Y
SFN 6 1 4.07 1.46E-07 1.68 3.03E-04 175793 Y
SH3PXD2B 5 0 1.28 1.83E-05 0.86 3.39E-04 174705 Y
SLC25A22 2 0.5 0.53 5.48E-04 0.53 1.51E-05 177542
SLC29A1 4 0 1.28 6.39E-04 0.58 6.90E-05 112759 Y
SMOC2 14 1 2.09 8.54E-07 2.29 6.23E-06 112562 Y
SOD3 5 1 1.53 1.20E-06 1.69 2.42E-05 109610 Y
TES 1 1 1.59 6.30E-07 1.38 2.16E-07 135269 Y
TF 7 1 4.77 3.16E-09 0.94 7.82E-04 091513 Y
TNFAIP2 8 0.625 1.84 3.75E-05 1.26 1.46E-04 185215 Y
TPM3 0 0 0.5 2.83E-05 1.32 6.05E-04 143549 Y
TRPV4 4 1 0.96 6.16E-04 0.69 1.65E-04 111199
TUBB2B 5 0 2.14 8.00E-06 1.01 3.01E-05 137285 Y
TYMP 2 0 1.31 2.96E-04 0.84 4.55E-04 025708
UPP1 5 1 1.75 8.31E-07 0.93 1.86E-05 183696 Y
Only genes with significant differences on all three omics levels (methylation, gene expression and protein abundance) are
shown. Gene DMPs in DMRs: differentially methylated probes at 0.1% FDR located in DMRs that overlap gene; Prop
PosBetaFC DMPs: proportion of gene DMPs in DMRs that show increased methylation in osteophytic cartilage; DMR: dif-
ferentially methylated region; logFC: log2-fold change (increase means higher value in osteophytic cartilage); FDR: false
discovery rate; ENSG: Ensembl gene ID, prefix with ENSG00000; O vs H 5% FDR: genes with significant differences between
chondrocytes from osteophytic and high-grade articular cartilage across all three molecular levels at 5% or lower FDR
(Y = yes). *Genes associated with OA in genome-wide association studies.
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controls). There was no significant excess of genetic as-
sociation in the 56 genes together (P= 0.2116 using
MAGMA, see Methods section).
Cross-omics pathway analysis
In an integrative comparison of osteophytic and low-grade
articular cartilage using all three molecular levels (see
Methods section), we identified 36 GO annotations as
significantly associated with the molecular changes
at 5% FDR (supplementary Table S5, available at
Rheumatology online). The most significant annotations
(Table 2; all FDR< 2%) include gene sets with links to
OA (reviewed e.g. in [3]), such as extracellular matrix or-
ganization and collagen catabolic process; skeletal
system development; inflammatory response; positive
regulation of the ERK1 and ERK2 cascade; and platelet
aggregation. A further annotation with highly significant
association (integrative FDR< 2%) and P < 0.05 on
each one of the omics levels was endodermal cell differ-
entiation (Table 2).
Replication of gene expression changes
A previous study [6] examined gene expression differ-
ences between osteophytic and low-grade articular cartil-
age in knee OA patients using a microarray. The authors
identified 31 genes with >20-fold change in gene expres-
sion and P< 0.005. Of these 31 genes, 18 are present in
our RNA sequencing data, and all have directionally con-
cordant effects (supplementary Table S6, available at
Rheumatology online; binomial P< 105). This includes
TF and ALDH1A2, which were identified as significantly
different between osteophytic and low-grade articular
cartilage on all three omics levels in this study.
Discussion
This study provides a systematic molecular characteriza-
tion of osteophytic chondrocytes in OA across genome-
wide methylation, gene and protein expression levels.
We have shown widespread molecular differences be-
tween chondrocytes from osteophytic and low-grade ar-
ticular OA chondrocytes (as previously seen for gene
expression in the knee), with similar but smaller differ-
ences between osteophytic and high-grade articular OA
chondrocytes. By contrast, there were far fewer signifi-
cant differences between chondrocytes from high- and
low-grade articular cartilage for any given FDR. In a
direct comparison, we have shown that the differences
between osteophytic chondrocytes and those from low-
grade cartilage are positively correlated with the differ-
ences between chondrocytes from high- and low-grade
articular cartilage. The correlation between these differ-
ences is observed despite the morphological and histolo-
gical dissimilarities between osteophytic and articular
tissues. One interpretation would be that, although both
tissues are subject to the disease process and the altered
internal joint milieu [4], osteophytic chondrocytes are
better able to respond in terms of new cartilage produc-
tion, which may represent attempted joint recovery (e.g.
as in the transient phenotype suggested by [6]). Moreover,
osteophytes principally develop at the periphery of the
articular surface in response to an altered mechanical
environment; chondrocyte proliferation is followed by
chondrocyte hypertrophy and endochondral ossification
within the osteophyte. Several of the genes and pathways
identified in this study are implicated in these processes.
Of the 56 genes with differences between osteophytic
and low-grade articular cartilage on all three molecular
levels, gene expression changes in Transferrin (TF),
TABLE 2 Most significant associations identified in the integrative gene set analysis
Gene Ontology annotation
DMR RNA Prot
FDR
N FC P-value N FC P-value N FC P-value
Extracellular matrix organization* 30 1.71 0.0026 40 1.48 0.0049 22 1.90 0.0072 0.0034
Gluconeogenesis 4 0.98 0.71 7 1.13 0.52 19 3.90 0.00001 0.0034
Positive regulation of cytosolic calcium
ion concentration
11 1.44 0.081 20 2.45 0.00001 3 1.85 0.24 0.0034
Skeletal system development* 22 2.02 0.0012 28 1.53 0.0028 12 2.27 0.002 0.0034
Inflammatory response 19 1.07 0.40 44 1.89 0.00001 8 1.09 0.43 0.0081
Endodermal cell differentiation* 9 2.55 0.0054 12 2.14 0.0056 6 2.11 0.036 0.011
Positive regulation of ERK1 and ERK2
cascade*
19 1.60 0.014 21 1.53 0.013 11 2.17 0.0042 0.012
Positive regulation of peptidyl-tyrosine
phosphorylation
10 1.61 0.079 18 1.94 0.0017 7 2.46 0.0032 0.012
Collagen catabolic process 16 2.27 0.0024 12 1.15 0.32 13 2.46 0.0013 0.012
Platelet aggregation* 8 1.95 0.048 12 1.71 0.027 11 2.71 0.002 0.016
All shown Gene Ontology terms are enriched in the cross-omics analysis at below 2% FDR. DMR: differentially methylated
region; RNA: gene expression; Prot: protein abundance; N: number of significant genes annotated to GO term; FC: fold-
change enrichment; P: within-omics empirical P-values for enrichment. FDR: integrative false-discovery rate based on com-
bination of the three-omics P-values (see Methods section). *The terms with enrichment P< 0.05 across all individual omics
analyses.
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MMP13 and ALDH1A2 have also been previously identi-
fied in the knee [6], indicating prominent involvement of
these genes. TF (reduced mRNA and protein levels in
osteophytic chondrocytes) is known to be produced in
hypertrophic cartilage as a pro-angiogenic molecule [17]
and is found in the synovial fluid of OA patients [18].
MMP13 (increased mRNA and protein levels in osteo-
phytic chondrocytes) is a marker of chondrocyte hyper-
trophy considered important in cartilage degeneration [19,
20]. ALDH1A2 is known to have genetic links to OA, dis-
cussed in detail below. The 56 genes with significant dif-
ferences across omics levels also include CILP (reduced
mRNA and protein levels in osteophytic chondrocytes),
which was previously found to be down-regulated in
mechanically induced OA in mice [21]; and IL6 (increased
mRNA and protein levels in osteophytic chondrocytes),
which has been localized to chondroblasts and preosteo-
blasts in human osteophytes during endochondral ossifi-
cation [22]. All of the genes highlighted above also show
evidence for differences between chondrocytes from
osteophytic and high-grade articular cartilage across all
three molecular levels at 5% or lower FDR.
Notably, the 56 genes with differences between chon-
drocytes from osteophytic and low-grade articular cartil-
age on all three molecular levels also include two genes
that harbor genetic variants robustly associated with OA
identified from genome wide association studies,
ALDH1A2 and COMP. ALDH1A2 (aldehyde dehydrogen-
ase 1 family, member A2 or retinaldehyde) is an enzyme
that catalyses the synthesis of retinoic acid, the active de-
rivative of vitamin A (retinol). Vitamin A is involved in post-
natal bone health and bone remodelling, with both high
and low levels having negative effects [23]. COMP is a
constituent of the cartilage matrix, present in the interterri-
torial matrix and is involved in collagen fibrillogenesis [24].
Notably, the decreased expression of both genes is con-
sistent across all three molecular levels in this study, and
consistent with the molecular mechanisms suggested for
the associated genetic variants (reduction of gene expres-
sion for ALDH1A2 and a missense variant in COMP). We
did not find such cross-omics significant changes of
ALDH1A2 or COMP between low- and high-grade articular
cartilage (with only protein-level changes ALDH1A2 signifi-
cant at 5% FDR), which could suggest that their action is
stronger in osteophytic cartilage, or could be due to the
limited power in this discovery study. However, we have
replicated gene expression changes of ALDH1A2 in osteo-
phytic cartilage using independent data. Interestingly, the
genetic association of ALDH1A2 was identified in severe
hand OA [16], which is characterized by node formation.
Using UK Biobank data, we did not find evidence for
association of the joint set of the 56 genes with differ-
ences between chondrocytes from osteophytic and low-
grade articular cartilage on all three molecular levels. It is
possible that some of these genes exhibit molecular
changes as a consequence rather than cause of the
disease, or are involved in OA progression rather than in-
cidence. The lack of association could also be due to still
limited sample size of the genetic data. Larger cohorts will
be required to determine the comprehensive set of gen-
etic variants associated with OA, as well as which molecu-
lar changes are causal to disease processes.
In the cross-omics GO analysis, several of the gene
annotations with highly significant associations have
known links to OA: changes in the extracellular matrix,
collagen catabolism, inflammation and activity of the
ERK cascade are all known interrelated processes
taking place in the OA joint [25]. The ERK signalling path-
way is important in mesenchymal cell differentiation and
can be regulated by mechanical stimuli during joint forma-
tion [26, 27]. Another annotation with highly significant
cross-omics association (integrative FDR< 2%) was
endodermal cell differentiation, which is not directly
linked to cartilage, but could reflect tissue development
factors involved in osteophyte formation.
We did not find cross-omics differences between
osteophytic and articular cartilage in previously reported
osteophyte development genes such as TGF, PTH and
IGF1 [4]. This could be explained by the small sample size
of the study, or the fact that the chondrocytes were taken
from patients with end-stage hip OA, so may not reflect
processes involved early in osteophyte development.
The major strengths of this study are the integration of
DNA methylation, gene expression and proteomics data,
for a comprehensive overview of the changes across mo-
lecular levels, and the precise matching of osteophytic,
low- and high-grade articular cartilage samples from the
same joint. The latter reduces the possibility of false-posi-
tives due to biological differences between individuals.
This approach has helped illuminate the molecular basis
of OA progression; tissue from healthy individuals and
early OA stages would be required to characterize the
onset of the disease. The main limitation of this study is
the size of the cohort examined here. As such, this study
is a proof-of-concept discovery study, and replication in
larger independent datasets will be required. The depos-
ition of all data in open repositories also allows the data to
be combined with other datasets in the future.
As noted above, the molecular associations identified
may be a result of, rather than causal to the disease pro-
cesses. Nonetheless, they can provide insights into char-
acteristics of osteophytic chondrocytes and into disease
progression, and suggest targets for further functional
follow-up with translational potential.
In summary, we present the first integrative methylation,
gene expression and proteomics study across osteo-
phytic and articular cartilage in hip OA. We have identified
multiple genes with significant cross-omics changes be-
tween osteophytic and low-grade articular cartilage,
including two genes associated with OA through
genome-wide association studies.
These findings offer evidence that the study of osteo-
phytic cartilage can provide distinct insight into OA
pathogenesis.
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